BIVALIRUDIN

Generic: BIVALIRUDIN

Mylan Institutional LLCManufacturer
INTRAVENOUSRoute
BIVALIRUDINActive Substance
2018-06-01Original Approval

BIVALIRUDIN is FDA application ANDA202471, sponsored by MYLAN INSTITUTIONAL. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Top Reported Reactions

1
DRUG INEFFECTIVE
200 reports
2
OFF LABEL USE
114 reports
3
HAEMORRHAGE
91 reports
4
HEPARIN-INDUCED THROMBOCYTOPENIA
76 reports
5
GASTROINTESTINAL HAEMORRHAGE
45 reports
6
THROMBOSIS
44 reports
7
VASCULAR STENT THROMBOSIS
40 reports
8
ACUTE MYOCARDIAL INFARCTION
36 reports
9
HYPOTENSION
33 reports
10
THROMBOSIS IN DEVICE
33 reports